



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application  
Breu, et al.

Group: 1624

Serial No. 09/939,883 filed August 27, 2001  
Docket No. 20725

Examiner: Truong, Tamthom Ngo

For: NEUROPEPTIDE Y ANTAGONISTS

TERMINAL DISCLAIMER

Nutley, New Jersey 07110  
August 12, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Hoffmann-La Roche Inc., a corporation of the state of New Jersey, having an office at 340 Kingsland Street, Nutley, New Jersey 07110, is the assignee of the entire right, title and interest in and to the invention described and claimed in the captioned application for Letters Patent of the United States, and in and to said application and in and to any and all Letters Patent of the United States which may issue from said application, by virtue of an Assignment by Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Heinrich Nettekoven and Philippe Pflieger to F.Hoffmann-La Roche AG, recorded in the United States Patent and Trademark Office on January 31, 2002 at reel 012655, frame 0173; an Assignment by F. Hoffmann-La

08/18/2004 ZJUHAR1 00000047 082525 09939883

01 FC:1814 110.00 DA

Roche AG to Hoffmann-La Roche Inc., recorded in the United States Patent and Trademark Office on January 31, 2002 at reel 012655, frame 0157.

Hoffmann-La Roche Inc. hereby certifies that the evidentiary documents have been reviewed, and, to the best of Hoffmann-La Roche Inc.'s knowledge and belief, title to the captioned application is in Hoffmann-La Roche Inc.

Hoffmann-La Roche Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the captioned application which would extend beyond the expiration date, including any extension obtained under 35 USC 156, of U.S. Patent No. 6,696,467 issued February 24, 2004.

Hoffmann-La Roche Inc. further agrees that any patent so granted on the captioned application, together with any right to recover for its violation, shall be enforceable only for and during such period that the legal title to any patent granted on the captioned application shall be the same as the legal title to U.S. Patent No. 6,696,467 issued February 24, 2004. This agreement to run with any patent granted on the captioned application and to be binding upon the grantee, its successors or assigns.

Hoffmann-La Roche Inc. does not disclaim the terminal part of the term of any patent granted on the captioned application prior to the expiration date of the full statutory term as

defined in 35 U.S.C. 154 to 156 and 173 of U.S. Patent No. 6,696,467 issued February 24, 2004, as presently shortened by any terminal disclaimer, in the event that said patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Hoffmann-La Roche Inc. makes the above disclaimer without prejudice to its rights to extend, under 35 U.S.C. 154-156, the term of any U.S. patent granted on the captioned application beyond the term provided by this Terminal Disclaimer.

The undersigned has authority to sign on behalf of Hoffmann-La Roche Inc. since he is an officer of Hoffmann-La Roche Inc.


The statutory fee of one hundred ten dollars (\$110.00) is being charged to Deposit Account No. 08-2525 as per the document submitted herewith in triplicate. The Commissioner is hereby authorized to charge any fees which may be required, or credit any over payment to Account No. 08-2525.


I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these

Serial No. 09/939,883

statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed at Nutley, State of New Jersey, this 12<sup>th</sup> day of August, 2004.



HOFFMANN-LA ROCHE INC  
By:   
George W. Johnston  
Vice President

144735